Synergistic effects of 15-deoxyspergualin with cyclosporine and the TCR-targeted monoclonal antibody R73 to induce specific unresponsiveness to skin allografts in rats.
Schorlemmer
H U
HU
Research Laboratories of Behringwerke AG, Marburg, Germany.
Dickneite
G
G
Kurrle
R
R
Seiler
F R
FR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use*; D004357:Drug Synergism; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006146:Guanidines / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D051381:Rats; D011914:Rats, Inbred BN; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D016038:Skin Transplantation / Q000276:immunology*; D013997:Time Factors; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D006146:Guanidines; D007166:Immunosuppressive Agents; D011948:Receptors, Antigen, T-Cell; D016572:Cyclosporine; C037258:gusperimus